Belgian biotech iTeos Therapeutics SA is heading across the Atlantic armed with $75m from a fresh funding round and a couple of promising cancer treatments.
The cash has come from an oversubscribed Series B financing which was led by MPM Capital, with participation from additional new investors HBM Partners, China's 6 Dimensions Capital and Curative Ventures. iTeos noted that all its existing backers - including Fund +, VIVES II and SRIW, as well as Pfizer Inc